在药物输送系统中的2,3-二甲基胺无水化物 (DMMA) 修改的纳米载体的进展
Pharmaceutics
|June 27, 2024
概括
具有电荷逆转能力的智能纳米药物,经过2,3-二甲基胺无水化物 (DMMA) 修改,可以克服瘤障碍. 这些先进的药物输送系统通过改善瘤透和细胞吸收来增强癌症治疗.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 在瘤学瘤学.
背景情况:
- 固体瘤存在复杂的物理障碍,阻碍了纳米医学的有效性.
- 目前的纳米药物在瘤微环境中的透和内化方面扎.
研究的目的:
- 审查用于增强癌症治疗的电荷逆转纳米药物的进展.
- 探索2,3-二甲基马氨酸无水化物 (DMMA) 在开发智能纳米载体中的作用.
主要方法:
- 专注于DMMA修饰的纳米载体对弱酸刺激有反应.
- 检查电荷逆转,外脱落,尺寸转移和连接体重新激活机制.
- 对针对性治疗的基于DMMA的药物输送系统的最新见解的审查.
主要成果:
- 在酸性瘤环境中,DMMA修饰使纳米载体能够从负电荷切换到正电荷.
- 电荷逆转增强了通过转细胞和细胞膜相互作用的瘤透.
- 通过调节纳米载体特性,DMMA衍生物促进了量身定制的治疗方法.
结论:
- 经DMMA修饰的纳米载体代表了克服癌症治疗挑战的有希望的战略.
- 这些智能系统为有针对性的药物输送提供了下一代方法.
- 对基于DMMA的纳米药物的进一步研究有可能改善癌症治疗结果.
相关概念视频
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


